Haemonetics Corporation Haemonetics Corporation

Haemonetics Corporation

HAE

Peringkat dalam Saham #3277
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Harga Saham
$118.26
Terakhir disinkronkan: 2026-10-20
Kapitalisasi Pasar
$5.38B
Perubahan (1 hari)
-0.20%
Perubahan (1 tahun)
131.02%
Negara
US
Perdagangan Haemonetics Corporation (HAE)

Kategori

Healthcare
Pendapatan untuk Haemonetics Corporation (HAE)
Pendapatan pada Jun 2026 TTM: $1.35B
Menurut laporan keuangan terbaru dari Haemonetics Corporation, pendapatan saat ini (TTM) adalah $1.35B. Pada tahun 2024, perusahaan menghasilkan pendapatan sebesar $1.31B peningkatan dibandingkan pendapatan pada tahun 2023 yang sebesar $1.17B. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Haemonetics Corporation dari 2000 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Mengubah
2026 (TTM) $1.35B -0.65%
2025 $1.36B 3.95%
2024 $1.31B 12.01%
2023 $1.17B 17.67%
2022 $993.20M 14.10%
2021 $870.46M -11.94%
2020 $988.48M 2.16%
2019 $967.58M 7.04%
2018 $903.92M 2.01%
2017 $886.12M -2.50%
2016 $908.83M -0.17%
2015 $910.37M -3.00%
2014 $938.51M 5.22%
2013 $891.99M 22.55%
2012 $727.84M 7.56%
2011 $676.69M 4.84%
2010 $645.43M 7.95%
2009 $597.88M 15.77%
2008 $516.44M 14.86%
2007 $449.61M 7.12%
2006 $419.73M 9.42%
2005 $383.60M 5.32%
2004 $364.23M 8.09%
2003 $336.96M 5.31%
2002 $319.97M 8.88%
2001 $293.86M 5.73%
2000 $277.92M 0.00%
Pendapatan untuk perusahaan serupa atau pesaing
Perusahaan Pendapatan Perbedaan Pendapatan Negara
$46.59B 3,345.60%
US
$35.48B 2,524.53%
IE
$25.84B 1,811.00%
US
$21.00B 1,452.94%
US
- -
DE